作者
Jiacai Yi,Yao Tian,Youchao Deng,Xinyu Gu,Xiangzheng Fu,Dejun Jiang,Aiping Lyu,Dongsheng Cao
摘要
Peptide therapeutics are expanding rapidly, yet poor permeability and limited in vivo stability still decide whether a candidate reaches the clinic. Judging these properties is difficult, because one sequence can be studied as different molecular forms or products, and reported values carry different experimental contexts. Despite the continuous accumulation of measurements of peptide absorption, distribution, metabolism, excretion, and toxicity (ADMET), few open-access resources keep each value attached to the material tested and its assay context. Herein, we present ADMETatlas, a curated peptide ADMET, safety, and developability database. Currently, ADMETatlas contains 39 641 measurements at 17 measured end points across 37 467 canonical peptide identities, 110 drug products, and 10 computed descriptors. Each measurement retains its value, unit, formal end point, assay context, and primary reference. Peptide identities, molecular forms, and products are cross-linked at the resolution each source supports. In addition to browsing and retrieval, a developability module profiles single candidates and compares several side by side. Applications to GLP-1 receptor agonists and polymyxin B show how route and formulation change the reading of peptide pharmacokinetics. We hope that ADMETatlas will prove useful in evidence-based peptide optimization and condition-aware modeling. ADMETatlas is freely available, without registration, at https://admetatlas.scbdd.com/.